Chimeric, humanized, or human antibody 2A4
US8404815B2 · kind B2 · utility
6Cited by
9References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 22, 2011 |
| Grant date | Mar 26, 2013 |
| Priority date | — |
| Expiry date | Feb 22, 2031 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/809
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.